[go: up one dir, main page]

PE20030563A1 - ANTIDIABETIC AGENTS - Google Patents

ANTIDIABETIC AGENTS

Info

Publication number
PE20030563A1
PE20030563A1 PE2002000822A PE2002000822A PE20030563A1 PE 20030563 A1 PE20030563 A1 PE 20030563A1 PE 2002000822 A PE2002000822 A PE 2002000822A PE 2002000822 A PE2002000822 A PE 2002000822A PE 20030563 A1 PE20030563 A1 PE 20030563A1
Authority
PE
Peru
Prior art keywords
phenyl
alkyl
aryl
ethyl
compounds
Prior art date
Application number
PE2002000822A
Other languages
Spanish (es)
Inventor
Christopher Franklin Bigge
Alexander James Bridges
Agustin Casmiro-Garcia
Stephen Alan Fakhoury
Hairong Zhou
Jessica Elizabeth Reed
Robert Philipp Schaum
Kevin Matthew Schlosser
Karen Elaine Sexton
Helen Tsenwhei Lee
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20030563A1 publication Critical patent/PE20030563A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I DONDE A ES UN ARILO, ARILO SUSTITUIDO, HETEROARILO, CICLOALQUILO C3-C7, CICLOALQUILO SUSTITUIDO; X ES UNA CADENA DE 2-5 ATOMOS DE LONGITUD; Q ES ARILO, HETEROARILO, HETEROARILO CONDENSADO; Y y Z SON (CR1R2)n Y (CR3R4)m SIENDO CADA UNO R1-R4 INDEPENDIENTE H, AHLO, ALQUILO C1-C6, OH, ALCOXI C1-C6; m Y n SON 1-3; B ES H, HALO, ALQUILO C1-C6, ENTRE OTROS; D ES H, -NH-ARILO, -NH-ARILO SUSTITUIDO, ENTRE OTROS; E ES COR5, SIENDO R5 ALQUILO C1-C6, OH, ALCOXI C1-C6, NR6R7, ENTRE OTROS; R6 Y R7 SON H, ALQUILO C1-C6; Y y Z SON CH2, B ES H Y E ES CO2H, D NO ES PIRROLILO. SON COMPUESTOS PREFERIDOS (R)-2-(2-{4-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-FENIL}-1-PIRROL-1-IL-ETIL)-5-PROPIL-1,3,4-OXADIAZOL; (R)-2-ETIL-5-(2-{4-[2-(5-METIL-2-FENIL-OXAZOL-4-IL)-ETOXI]-FENIL}-1-PIRROL-1-IL-ETIL)-5-PROPIL-1,3,4-OXADIAZOL; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION, COMPUESTOS INTERMEDIOS Y COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS SON UTILES EN EL TRATAMIENTO DE DIABETESREFERS TO COMPOUNDS OF FORMULA I WHERE A IS AN ARYL, SUBSTITUTED ARYL, HETEROARYL, C3-C7 CYCLOALKYL, SUBSTITUTED CYCLOALKYL; X IS A CHAIN OF 2-5 ATOMS IN LENGTH; Q IS ARYL, HETEROARYL, CONDENSED HETEROARYL; Y and Z ARE (CR1R2) n Y (CR3R4) m R1-R4 EACH BEING INDEPENDENT H, AHLO, C1-C6 ALKYL, OH, C1-C6 ALCOXY; m AND n ARE 1-3; B IS H, HALO, C1-C6 ALKYL, AMONG OTHERS; D IS H, -NH-ARYL, -NH-SUBSTITUTED ARYL, AMONG OTHERS; E IS COR5, R5 BEING C1-C6 ALKYL, OH, C1-C6 ALCOXY, NR6R7, AMONG OTHERS; R6 AND R7 ARE H, C1-C6 ALKYL; Y and Z ARE CH2, B IS H AND E IS CO2H, D IS NOT PYRROLYL. PREFERRED COMPOUNDS ARE (R) -2- (2- {4- [2- (5-METHYL-2-PHENYL-OXAZOL-4-IL) -ETOXY] -PHENYL} -1-PIRROL-1-IL-ETHYL) -5-PROPYL-1,3,4-OXADIAZOLE; (R) -2-ETHYL-5- (2- {4- [2- (5-METHYL-2-PHENYL-OXAZOL-4-IL) -ETOXY] -PHENYL} -1-PYRROL-1-IL-ETHYL ) -5-PROPYL-1,3,4-OXADIAZOLE; AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR THE PREPARATION, INTERMEDIATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS. THE MENTIONED COMPOUNDS ARE USEFUL IN THE TREATMENT OF DIABETES

PE2002000822A 2001-08-29 2002-08-27 ANTIDIABETIC AGENTS PE20030563A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31572801P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
PE20030563A1 true PE20030563A1 (en) 2003-06-23

Family

ID=23225787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000822A PE20030563A1 (en) 2001-08-29 2002-08-27 ANTIDIABETIC AGENTS

Country Status (35)

Country Link
EP (2) EP1577305A1 (en)
JP (1) JP2005504778A (en)
KR (1) KR20040044515A (en)
CN (1) CN1558897A (en)
AP (1) AP2002002616A0 (en)
AR (1) AR036301A1 (en)
AT (1) ATE323674T1 (en)
BG (1) BG108597A (en)
BR (1) BR0212069A (en)
CA (1) CA2458621A1 (en)
CZ (1) CZ2004272A3 (en)
DE (1) DE60210784T2 (en)
EA (1) EA200400140A1 (en)
EC (1) ECSP044999A (en)
EE (1) EE200400075A (en)
ES (1) ES2260456T3 (en)
GT (1) GT200200175A (en)
HN (1) HN2002000242A (en)
HR (1) HRP20040164A2 (en)
HU (1) HUP0401620A2 (en)
IL (1) IL159886A0 (en)
IS (1) IS7114A (en)
MA (1) MA27135A1 (en)
MX (1) MXPA04001968A (en)
NO (1) NO20040881L (en)
OA (1) OA12653A (en)
PA (1) PA8553701A1 (en)
PE (1) PE20030563A1 (en)
PL (1) PL369569A1 (en)
SK (1) SK1182004A3 (en)
SV (1) SV2003001213A (en)
TN (1) TNSN04038A1 (en)
UY (1) UY27424A1 (en)
WO (1) WO2003018553A1 (en)
ZA (1) ZA200400374B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003203170A1 (en) * 2002-01-17 2003-07-30 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
PA8594401A1 (en) * 2003-02-21 2004-09-16 Pfizer CARBOXILIC ACIDS OF HETEROARILO CONDENSED AS A PPAR AGONIST
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp Indole acetic acid derivatives and their use as pharmaceutical agents
WO2005000841A1 (en) * 2003-06-27 2005-01-06 Warner-Lambert Company Llc Preparation of n2-alkylated 1,2,3-triazoles
BRPI0412236A (en) * 2003-07-02 2006-09-12 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the treatment and / or prevention of diseases that are modulated by ppar (delta) and / or ppar (alpha) agonists, and use of these compounds
AU2004259738B2 (en) * 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
CN100509802C (en) * 2003-11-05 2009-07-08 霍夫曼-拉罗奇有限公司 Heteroaryl deravatives as PPAR activators
CN1886133B (en) 2003-12-04 2010-12-01 财团法人卫生研究院 Indole compounds
ES2285554T3 (en) 2003-12-11 2007-11-16 GALDERMA RESEARCH & DEVELOPMENT NEW COMPOUNDS THAT ARE MODULATORS OF PPAR TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
FR2863610B1 (en) * 2003-12-11 2006-01-20 Galderma Res & Dev NOVEL MODULATING COMPOUNDS OF PPAR-TYPE RECEPTORS AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4599395B2 (en) * 2004-03-09 2010-12-15 エフ．ホフマン−ラ ロシュ アーゲー Pyrazolyl indolyl derivatives as PPAR activators
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
NZ572268A (en) * 2006-04-18 2011-09-30 Nippon Chemiphar Co Activating agent for peroxisome proliferator activated receptor delta (ppar)
PE20080188A1 (en) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv DERIVATIVES OF BENZOAZEPINE-OXY-ACETIC ACID AS PPAR-DELTA AGONISTS USED TO INCREASE HDL-C, REDUCE LDL-C AND REDUCE CHOLESTEROL
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
PT2277874T (en) 2008-04-15 2018-08-10 Nippon Chemiphar Co Activator for peroxisome proliferator-activated receptor
FR2976942B1 (en) * 2011-06-23 2013-07-12 Metabolys PIPERAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF IN THE TREATMENT OF INSULIN RESISTANCE
FR2976943B1 (en) 2011-06-23 2013-07-12 Metabolys PIPERAZINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF IN THE TREATMENT OF INSULIN RESISTANCE
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
WO2025141118A1 (en) * 2023-12-27 2025-07-03 Institut National de la Santé et de la Recherche Médicale Arylalkyloxyindole compounds and derivatives and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941777D1 (en) * 1998-03-10 2010-01-21 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES AND MEDICAMENTS CONTAINING THESE AS ACTIVE ACTIVE SUBSTANCES
AU1120599A (en) * 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
JP2002527507A (en) * 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ New compounds, their preparation and use
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
NZ515284A (en) * 1999-04-28 2004-12-24 Dr Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
EP1210345B1 (en) * 1999-09-08 2004-03-03 Glaxo Group Limited Oxazole ppar antagonists

Also Published As

Publication number Publication date
ATE323674T1 (en) 2006-05-15
ECSP044999A (en) 2004-04-28
HUP0401620A2 (en) 2004-11-29
SV2003001213A (en) 2003-03-18
BR0212069A (en) 2004-07-20
CN1558897A (en) 2004-12-29
MA27135A1 (en) 2005-01-03
BG108597A (en) 2005-03-31
HN2002000242A (en) 2002-12-12
NO20040881L (en) 2004-04-19
DE60210784T2 (en) 2006-11-02
JP2005504778A (en) 2005-02-17
ES2260456T3 (en) 2006-11-01
WO2003018553A1 (en) 2003-03-06
UY27424A1 (en) 2003-03-31
DE60210784D1 (en) 2006-05-24
TNSN04038A1 (en) 2006-06-01
IL159886A0 (en) 2004-06-20
HRP20040164A2 (en) 2004-10-31
EE200400075A (en) 2004-08-16
CA2458621A1 (en) 2003-03-06
SK1182004A3 (en) 2005-03-04
CZ2004272A3 (en) 2005-02-16
WO2003018553A8 (en) 2004-04-08
KR20040044515A (en) 2004-05-28
MXPA04001968A (en) 2004-06-07
PA8553701A1 (en) 2003-07-28
EP1423363A1 (en) 2004-06-02
ZA200400374B (en) 2005-03-30
OA12653A (en) 2006-06-16
EA200400140A1 (en) 2004-08-26
EP1423363B1 (en) 2006-04-19
AR036301A1 (en) 2004-08-25
IS7114A (en) 2004-01-15
PL369569A1 (en) 2005-05-02
EP1577305A1 (en) 2005-09-21
GT200200175A (en) 2003-05-23
AP2002002616A0 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
PE20030563A1 (en) ANTIDIABETIC AGENTS
DOP2001000271A (en) IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS.
ATE260263T1 (en) HETEROAROMATIC BIZYCLIC COMPOUNDS HAVING ANTI-CANCER EFFECT
RU2005134162A (en) NEW COMPOUNDS WITH ANTIBACTERIAL ACTION
BR0108893B1 (en) pharmaceutical composition containing azetidine derivatives, azetidine derivative compound, and process for the preparation of compounds.
PE20020084A1 (en) N- (SUBSTITUTED GLYCYL) -2-CYANO-PYRROLIDINES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV
PE20020476A1 (en) GLUCOPYRANOSILOXYBENZYLBENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
AR047898A1 (en) SUBSTITUTED BENZAMIDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES
DK1767535T3 (en) Synthesis of epothilones, their intermediates, analogs and their use
PT928788E (en) PHARMACEUTICALLY ACTIVE COMPOUNDS
DK0657422T3 (en) Naphthyloxyacetic acid derivatives such as PEG2 agonists and antagonists
PE20040531A1 (en) DERIVATIVES OF ISOINDOLONE, PREPARATION PROCESS, INTERMEDIATE COMPOUNDS OF THIS PROCESS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PE109798A1 (en) PROCEDURE AND INTERMEDIATES TO PREPARE SUBSTITUTED CHROMANOL DERIVATIVES
RU2004125609A (en) ALPHA-2-DELTA-LIGAND COMBINATIONS WITH A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
BRPI0617918B8 (en) compounds of formula (i) and their use, medicines and pharmaceutical composition
RU2003130070A (en) BIGUANID DERIVATIVES
NO961077L (en) Substituted benzoltienylpiperazines, their use as drugs and methods of preparation
PE20030929A1 (en) 3- (IMIDAZOLIL) -2-ALCOXYPROPANOIC ACIDS
RU94032285A (en) Cephalosporin compounds, process for preparation thereof
EA200400666A2 (en) New benzothiazine and benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them
EA200500683A1 (en) NEW COMPOUNDS OF PYRROLIDINE AND THIAZOLIDINE, THEIR METHOD FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PE20050139A1 (en) COMPOUNDS DERIVED FROM HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS
ES2183500T3 (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NO20053997L (en) Oligosaccharidderivat
DK1065206T3 (en) Tetrazolylalkylindole compounds as anti-inflammatory and analgesic agents

Legal Events

Date Code Title Description
FD Application declared void or lapsed